Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases
Authors
Keywords
Liver metastases, Colorectal cancer, Bevacizumab, Cetuximab, Pathological response, Neoadjuvant chemotherapy
Journal
MEDICAL ONCOLOGY
Volume 32, Issue 7, Pages -
Publisher
Springer Nature
Online
2015-05-23
DOI
10.1007/s12032-015-0638-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- KRASstatus and outcome of liver resection after neoadjuvant chemotherapy including bevacizumab
- (2012) S. Stremitzer et al. BRITISH JOURNAL OF SURGERY
- Resectability and outcome with anti-EGFR agents in patients with KRAS wild-type colorectal liver-limited metastases: a meta-analysis
- (2012) F. Petrelli et al. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
- Optimal Morphologic Response to Preoperative Chemotherapy: An Alternate Outcome End Point Before Resection of Hepatic Colorectal Metastases
- (2012) Junichi Shindoh et al. JOURNAL OF CLINICAL ONCOLOGY
- Pathologic response to bevacizumab-containing chemotherapy in patients with colorectal liver metastases and its correlation with survival
- (2012) T. Gruenberger et al. SURGICAL ONCOLOGY-OXFORD
- A Systematic Review of Clinical Response and Survival Outcomes of Downsizing Systemic Chemotherapy and Rescue Liver Surgery in Patients with Initially Unresectable Colorectal Liver Metastases
- (2011) Vincent W. T. Lam et al. ANNALS OF SURGICAL ONCOLOGY
- KRAS Mutation Is Associated with Lung Metastasis in Patients with Curatively Resected Colorectal Cancer
- (2011) J. Tie et al. CLINICAL CANCER RESEARCH
- Increased Detection Sensitivity for KRAS Mutations Enhances the Prediction of Anti-EGFR Monoclonal Antibody Resistance in Metastatic Colorectal Cancer
- (2011) F. Molinari et al. CLINICAL CANCER RESEARCH
- Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
- (2011) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor Thickness at the Tumor-normal Interface: A Novel Pathologic Indicator of Chemotherapy Response in Hepatic Colorectal Metastases
- (2010) Dipen M. Maru et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Bevacizumab Improves Pathological Response of Colorectal Cancer Liver Metastases Treated with XELOX/FOLFOX
- (2010) Markus Klinger et al. ANNALS OF SURGICAL ONCOLOGY
- Extended Preoperative Chemotherapy Does Not Improve Pathologic Response and Increases Postoperative Liver Insufficiency After Hepatic Resection for Colorectal Liver Metastases
- (2010) Yoji Kishi et al. ANNALS OF SURGICAL ONCOLOGY
- Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer
- (2010) Inti Zlobec et al. INTERNATIONAL JOURNAL OF CANCER
- Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel
- (2009) B. Nordlinger et al. ANNALS OF ONCOLOGY
- Evaluation of Long-term Survival After Hepatic Resection for Metastatic Colorectal Cancer
- (2009) Myrddin Rees et al. ANNALS OF SURGERY
- KRAS Mutation Correlates With Accelerated Metastatic Progression in Patients With Colorectal Liver Metastases
- (2009) Garrett M. Nash et al. ANNALS OF SURGICAL ONCOLOGY
- Association of Computed Tomography Morphologic Criteria With Pathologic Response and Survival in Patients Treated With Bevacizumab for Colorectal Liver Metastases
- (2009) Yun Shin Chun JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial
- (2009) Gunnar Folprecht et al. LANCET ONCOLOGY
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- (2009) Eric Van Cutsem et al. NEW ENGLAND JOURNAL OF MEDICINE
- PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients
- (2008) F. Perrone et al. ANNALS OF ONCOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Complete Pathologic Response After Preoperative Chemotherapy for Colorectal Liver Metastases: Myth or Reality?
- (2008) René Adam et al. JOURNAL OF CLINICAL ONCOLOGY
- Pathologic Response to Preoperative Chemotherapy: A New Outcome End Point After Resection of Hepatic Colorectal Metastases
- (2008) Dan G. Blazer et al. JOURNAL OF CLINICAL ONCOLOGY
- Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
- (2008) Bernard Nordlinger et al. LANCET
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- (2008) Christos S. Karapetis et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started